Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 13 of 5804
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingA Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
One-Time gene injection aims to rescue sight in rare childhood blindness
Disease control Not yet recruitingThis study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a …
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Light-Activated therapy targets pancreatic tumors during surgery
Disease control Not yet recruitingThis is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
Phase: PHASE1, PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemotherapy-Free combo aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingPatients with diffuse large B-cell lymphoma (DLBCL) who are primary refractory to first-line R-CHOP therapy or relapse within 12 months after R-CHOP have a poor prognosis and limited treatment options. Conventional salvage chemotherapy has limited efficacy, and CAR-T cell therapy…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a simple oxygen mask boost stroke recovery hours after symptoms start?
Disease control Not yet recruitingAlthough endovascular therapy (EVT) has substantially improved recanalization rates and extended the treatment window for acute ischemic stroke, fewer than half of patients achieve functional independence despite successful reperfusion. Growth of the ischemic core before reperfus…
Phase: PHASE3 • Sponsor: Weifang Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for sickle cell: Half-Matched transplants aim to cut complications
Disease control Recruiting nowThe purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survi…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
Diagnosis Not yet recruitingPancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates. Many PDACs arise from non-invasive precursor lesions that develop over years, including pancreatic in…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control Not yet recruitingThis is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Phase: PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Stem cell combo shows promise for deadly transplant complication
Disease control Not yet recruitingThis study is a randomized, double-blind, placebo-controlled, multicenter Phase III trial to compare the efficacy and safety of remestemcel-L-rknd (remestemcel-L), ex-vivo cultured adult human mesenchymal stromal cells (MSC), combined with ruxolitinib vs. ruxolitinib combined wit…
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a new drug slow lung scarring in IPF?
Disease control Not yet recruitingThis is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.
Phase: PHASE3 • Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combination targets rare childhood leukemia that resists standard treatment
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Revumenib in combination with Fludarabine and Cytarabine can treat children with NUP98-rearranged relapsed or refractory Acute Myeloid Leukemia. The main question it aims to answer is: What is the Best Overall Response Rate by morph…
Phase: PHASE2 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Community-Driven strategies aim to end intergenerational type 2 diabetes in indigenous children
Prevention Not yet recruitingThe overall objective: to co-design and implement targeted and timely community led strategies to improve the health of the Next Generation and end the intergenerational impact of T2D in this population.
Phase: NA • Sponsor: University of Manitoba • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
AI-Designed drug targets scarred lungs in major trial
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018\_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis. The purpose of this study is to evaluate if Rentosertib …
Phase: PHASE3 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could an antibody boost chemo for tough blood cancers?
Disease control Not yet recruitingThis phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune ce…
Phase: PHASE2, PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
Disease control Not yet recruitingThis clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype non-small cell lung cancer (NSCLC) in adults. It will also…
Phase: PHASE2, PHASE3 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a new drug boost chemotherapy for a rare cancer?
Disease control Not yet recruitingThis trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of adva…
Phase: PHASE3 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New Dual-Action antibody could extend lives in stomach cancer
Disease control Not yet recruitingThe goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or me…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New quadrivalent meningitis vaccine aims to shield China's youngest from deadly infection
⭐️ VACCINE ⭐️ Not yet recruitingThe purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after …
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat brain tumors
Disease control Not yet recruitingThis phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkyl…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental drug aims to halt rare neurological decline
Disease control Not yet recruitingThe purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC